Following the grant of the MA for Avastin and after its off-label use in ophthalmology had become widespread in Italy, in May 2007, the AIFA included that use in List 648 in connection with the treatment of exudative macular diseases (AMD, retinal vein occlusion (RVO), diabetic macular edema (DME), myopic macular degeneration (MMD)) and neovascular glaucoma, there being no valid therapeutic alternative at that time for treating those diseases.
Het voorstel voor een richtlijn wijzigt de fiscale plaats van dienstverlening tussen belastingplichtigeneurlex-diff-2017 eurlex-diff-2017